TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00940355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention pulmonary nurse
Description: The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
Study: NCT01507272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
Study: NCT01898065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-F-MISO
Description: PET scan with the 18 Fluoro Misonidazole
Study: NCT05300191

Intervention type: DIAGNOSTIC_TEST
Intervention: Effluent dialysate
Description: Effluent dialysate samples evaluated for evidence of peritonitis
Study: NCT02114580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical training
Description: Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).~Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical training
Description: Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).~Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises.
Study: NCT02510287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Fentanyl Initial Dose
Description: 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Fentanyl Initial Dose
Description: 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Fentanyl: Continuous Epidural Infusion
Description: 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus
Description: A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Bolus
Description: Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Bolus
Description: Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
Study: NCT03912129

Intervention type: GENETIC
Group type: OTHER
Intervention: blood sample
Description: A first systematic approach by Targeted-Next Generation Sequencing will be used on the entire cohort of patients with pSE. This step will be performed on a sequencing chip specifically developed to detect anomalies in known genes involved in autoimmunity.~In patients for whom no mutations are identified, a whole exome sequencing (WES) approach will be applied to patients and their parents to seek to identify mutations in new genes that may be related to pSE.~In patients for whom this WES approach is unsuccessful, the search for somatic lymphocyte mutations, or copy number variants will be performed before considering a complete genome sequencing .~If several candidate genes are identified, the clinical data provided by the CEREVANCE and the phenotypic analyses carried out prior to genetic analyses by the CEDI laboratory will guide the choices to prioritize the study of the identified variants.
Study: NCT03355183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetics
Description: Isokinetics, or accommodating resistance, is a form of exercise where a person provides a maximum muscle contraction against a resistance or lever arm, (isokinetic dynamometer) at a fixed speed through a given range of motion. This type of muscle action can be done either concentrically or eccentrically at the given joint.
Study: NCT05183503

Intervention type: DIAGNOSTIC_TEST
Intervention: DC/TMD examination
Description: Clinical examination by examiners- experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the official website of the International Network for Orofacial Pain and Related Disorders Methodology
Study: NCT03302754

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab
Description: Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
Study: NCT03948178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan 1 mg capsule for oral administration
Study: NCT02009527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-hydroxy-nor-arginine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study: NCT03190200

Intervention type: DEVICE
Intervention: MRI
Description: No intervention - observational trial using MRI
Study: NCT02639780

Intervention type: OTHER
Intervention: protein expression pattern of packed red blood cells
Description: the proteome of packed red blood cells will be assessed at predefined time points

Intervention type: OTHER
Intervention: protein expression pattern of packed red blood cells
Description: the proteome of packed red blood cells will be assessed at predefined time points

Intervention type: OTHER
Intervention: protein expression pattern of packed red blood cells
Description: the proteome of packed red blood cells will be assessed at predefined time points

Intervention type: OTHER
Intervention: protein expression pattern of packed red blood cells
Description: the proteome of packed red blood cells will be assessed at predefined time points

Intervention type: OTHER
Intervention: protein expression pattern of packed red blood cells
Description: the proteome of packed red blood cells will be assessed at predefined time points

Intervention type: OTHER
Intervention: protein expression pattern of packed red blood cells
Description: the proteome of packed red blood cells will be assessed at predefined time points
Study: NCT02776163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: nedaplatin 35mg/m\^2，D1-2，2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: nedaplatin 35mg/m\^2，D1-2，2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 70mg/m\^2，D1，2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 70mg/m\^2，D1，2 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 60-66Gy in 30-33 fractions over 6-7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 60-66Gy in 30-33 fractions over 6-7 weeks
Study: NCT01934283

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: urine folly catheter
Study: NCT01065974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Therapy
Description: Weight loss using CBT and continued CBT during weight loss maintenance.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal Replacements
Description: Weight loss using CBT and meal replacements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritrol
Description: To make widespread nutritional changes to participants personal food environments.
Study: NCT02432235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camidanlumab tesirine
Description: Intravenous (IV) infusion.
Study: NCT00282503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen+ECP, Methylprednisolone
Description: Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~* Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~* Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be \> 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methoxsalen+ECP, Methylprednisolone
Description: Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~* Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~* Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be \> 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ecp
Description: ECP or Extra Corporeal Phototherapy will be used with UVADex
Study: NCT05836337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tattoo- Black Eye
Description: Device name: Black eye Manufacturer: The Standard Co., Ltd

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clip- HydroMARK
Description: Device name: HydroMARK Manufacturer: Biopsy Sciences, LLC
Study: NCT02275338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel
Description: 120mg administered via deep subcutaneous injection at Day 0 and Day 28.
Study: NCT00948870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shugan decoction
Description: Decoction ,two times a day,one bag of decoction one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shugan decoction
Description: Decoction ,two times a day,one bag of decoction one time
Study: NCT00382993

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Combination Product (sumatriptan succinate/naproxen sodium)
Description: Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.

Intervention type: DRUG
Group type: OTHER
Intervention: Combination Product (sumatriptan succinate/naproxen sodium)
Description: Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
Study: NCT02615743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Text message reminder
Description: Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Inhaled steroid canister monitor
Description: An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaled steroid canister monitor
Description: An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
Study: NCT04621695

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RBL
Description: Both arms are standard care procedures in the Netherlands

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemorrhoidectomy
Description: Both arms are standard care procedures in the Netherlands
Study: NCT02375503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium/Vitamin D
Description: Daily, calcium and vitamin D fortified snack bar
Study: NCT03182244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Tablet administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Once/twice daily Intravenously (IV)/subcutaneously (SC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Once daily IV injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Once daily IV injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Once daily IV/SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Once daily IV injection.
Study: NCT03509402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm
Description: Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm
Description: Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
Study: NCT03039751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AdvVEGF-D
Description: AdvVEGF-D will be injected into 10 sites of the myocardium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Rx
Description: Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
Study: NCT02278744

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: single-fraction radiation
Description: Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 17 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI and/or CT
Study: NCT01606215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: 1.0-2.0 million cells/kg body weight

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01064128

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic hysterectomy
Description: conventional 3 or 4 ports laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPA laparoscopic hysterectomy
Description: single-port access laparoscopic hysterectomy
Study: NCT03100305

Intervention type: OTHER
Intervention: Collection of blood and urine
Description: Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition

Intervention type: OTHER
Intervention: Collection of blood and urine
Description: Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition

Intervention type: OTHER
Intervention: Collection of blood and urine
Description: Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition

Intervention type: OTHER
Intervention: Collection of blood and urine
Description: Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition
Study: NCT03748641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive niraparib 200 mg capsules or tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive niraparib 200 mg capsules or tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Participants will receive AA 1000 mg tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Participants will receive AA 1000 mg tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 10 mg tablets daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 10 mg tablets daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 10 mg tablets daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation of Niraparib and Abiraterone Acetate (AA)
Description: Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.